E-Book | June 12, 2020

Novel Research In The Cell And Gene Sector

Source: Cell & Gene

The novel cell and gene therapies in the development pipeline today are the result of years of pioneering research by world-class, U.S.-based academic universities and biopharmaceutical research companies. Given the number of clinical trials in various stages, the U.S. Food and Drug Administration (FDA) expects that it will receive more than 200 investigational new drug applications a year through 2025. Additionally, the FDA estimates it will approve up to 20 cell and gene therapy products a year by 2025. The development of cell and gene therapies has become an essential component of cancer and genetic disease research and treatment. As such, there has been a great deal of financing funneling toward cell and gene therapy research, with companies raising nearly $2.6 billion in the third quarter of 2019. Provided are articles that help pose and answer questions around the research element of cell and gene therapy. 

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene